Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
6R)-2-hydrogenio-4
which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD)
The percentage of cells in G0/G1 phase increases in a time-dependent manner
19)11-5-2-9(14)3-6-11/h2-8H
Thalidomide-NH-C8-NH2 2688 6R)-2-hydrogenio-4Thalidomide NH C8 NH2 is a synthesized E3 ligase ligand linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. Product information CAS Number: 1957236 36 0 Molecular Weight: 400. 47 Formula: C21H28N4O4 Chemical Name: 4 [(8 aminooctyl)amino] 2 (2,6 dioxopiperidin 3 yl) 2,3 dihydro 1H isoindole 1,3 dione Smiles: NCCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O InChiKey: YVIZBYPPHMBVPA UHFFFAOYSA
US$ 50.00
US$ 143.00
US$ 497.50
US$ 30.00
US$ 525.00
US$ 467.50
US$ 700.00